Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. (Q49885709)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. |
scientific article |
Statements
1 reference
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. (English)
1 reference
Caina Li
1 reference
Miaomiao Yang
1 reference
Xiaofeng Wang
1 reference
Hua Zhang
1 reference
Chenjiang Yao
1 reference
Sujuan Sun
1 reference
Quan Liu
1 reference
Hao Pan
1 reference
Shuainan Liu
1 reference
Yi Huan
1 reference
Shengnan Li
1 reference
Jun Cao
1 reference
Xing Wang
1 reference
Yong Guo
1 reference
Nan Guo
1 reference
Shuqian Jing
1 reference
Cheng Zhang
1 reference
Zhufang Shen
1 reference
17 January 2018
1 reference
1 reference
150
1 reference
46-53
1 reference
Identifiers
1 reference
1 reference